Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Inclusion Criteria

• •1. Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
• •2. Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
• •3. Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
• •4. ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
• •5. Evidence of plaque psoriasis in a non-scalp area
• •6. Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis